Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study

Journal of Neurology
Ilya AyzenbergNeuromyelitis Optica Study Group

Abstract

Glatiramer acetate (GA) is an approved therapy for relapsing-remitting multiple sclerosis, but its efficacy for the prevention of attacks in neuromyelitis optica spectrum disorder (NMOSD) remains unknown. We did a multicenter retrospective analysis of GA-treated patients with NMOSD, identified through a national registry. Annualized relapse rate and expanded disability status scale (EDSS) were the main outcome measures. We identified 23 GA-treated patients (21 female, 16 aquaporin-4 antibody-positive). GA was given for <6 months in seven patients; reasons for stopping were relapses (n = 3), confirmation of NMOSD (n = 2) and side effects (n = 2). Of 16 patients treated ≥ 6 months with GA (15 female, 11 aquaporin-4 antibody-positive), 14 experienced at least one relapse. There was no reduction in the mean annualized relapse rate in the total group (1.9 ± 1.1 before vs. 1.8 ± 1.4 during GA therapy), as well as in those patients who were aquaporin-4 antibody-positive, or had a history of prior immunotherapy or not. The median EDSS increased (2.5 start vs. 3.5 finish of GA, P < 0.05). GA therapy was discontinued in 15/16 patients; reasons were therapeutic inefficacy in 13 and post-injection skin reactions in two patients. We conclud...Continue Reading

References

May 24, 2003·Brain : a Journal of Neurology·Roberto Bergamaschi
Jun 2, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·K GartzenN Putzki
Oct 24, 2008·Brain : a Journal of Neurology·S JariusW Kristoferitsch
Nov 26, 2009·Annals of Neurology·Monika BradlHans Lassmann
Jun 10, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J SellnerB Hemmer
Mar 15, 2011·Medical Hypotheses·Kai-Chen WangChing-Piao Tsai
Feb 15, 2012·Archives of Neurology·Ingo KleiterUNKNOWN Neuromyelitis Optica Study Group
Apr 11, 2012·Journal of Clinical Apheresis·Bhupendra O KhatriWilliam Verre
Nov 10, 2012·Journal of Neurology, Neurosurgery, and Psychiatry·Philippe CabreUNKNOWN Aegis of French National Observatory of Multiple Sclerosis
Mar 8, 2013·Journal of Neurology, Neurosurgery, and Psychiatry·Joanna KitleyJackie Palace
Apr 27, 2013·Annals of the New York Academy of Sciences·Meike MitsdoerfferThomas Korn
Nov 26, 2013·Journal of Neurology·Corinna TrebstUNKNOWN Neuromyelitis Optica Study Group (NEMOS)
Mar 29, 2014·Clinical and Experimental Immunology·S JariusF Paul
Jan 31, 2015·Neurology. Neuroimmunology and Neuroinflammation·Scott S Zamvil, Anthony J Slavin
Jun 21, 2015·Neurology·Dean M WingerchukUNKNOWN International Panel for NMO Diagnosis
Nov 26, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ingo Kleiter, Ralf Gold

❮ Previous
Next ❯

Citations

Oct 27, 2016·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·H ChenH Zhou
Nov 3, 2016·Journal of Neuroinflammation·Sven JariusUNKNOWN in cooperation with the Neuromyelitis Optica Study Group (NEMOS)
Mar 7, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Eoin P Flanagan, Brian G Weinshenker
Apr 8, 2017·Mayo Clinic Proceedings·Brian G Weinshenker, Dean M Wingerchuk
Dec 28, 2018·Expert Review of Neurotherapeutics·Frederike C OertelFriedemann Paul
Oct 27, 2018·Seminars in Immunopathology·Stefan M GoldManuel A Friese
Aug 12, 2017·Nature Reviews. Neurology·Andrew J Solomon, John R Corboy
Jun 5, 2019·Continuum : Lifelong Learning in Neurology·Tanuja Chitnis
Jan 5, 2020·BMJ Case Reports·James Kerr GrieveJonathan O'Riordan
Apr 2, 2020·Expert Opinion on Biological Therapy·Ankelien DuchowJudith Bellmann-Strobl
Jun 20, 2020·Neurology·Patrick Waters, Jacqueline Palace
Oct 25, 2017·Brain Sciences·Rana K ZabadKathleen M Healey
May 4, 2018·Current Treatment Options in Neurology·Grace Y Gombolay, Tanuja Chitnis
Mar 19, 2020·Neurology. Neuroimmunology and Neuroinflammation·Darius HäuslerMartin S Weber
Feb 22, 2018·Expert Opinion on Investigational Drugs·Friedemann PaulMichael Levy
Oct 14, 2018·CNS Drugs·Stefanie KuertenTimothy L Vollmer
Mar 16, 2017·Journal of Neurology·Daniel WhittamAnu Jacob
Nov 9, 2018·Frontiers in Neurology·Nadja BorisowFriedemann Paul
Jul 28, 2020·International Journal of Molecular Sciences·Jan TraubMartin S Weber
Aug 1, 2020·Expert Opinion on Emerging Drugs·Ankelien DuchowJudith Bellmann-Strobl
Nov 11, 2020·Neurodegenerative Disease Management·Ankelien Duchow, Judith Bellmann-Strobl

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.